06.01.26 -- Why Is Biopharma Left Out Of The U.S. Infrastructure Conversation?

Process development and optimization enabled efficient scale‑up of a complex lung cancer therapy, improving yields, reducing costs, and supporting rapid clinical and commercial progress.

Discover how solvent‑free, solid‑state stress testing speeds degradation studies, yields realistic impurity profiles, and provides earlier, material‑efficient insight into drug stability and risk.

The complex biology of rare diseases creates unique hurdles, making it difficult to design and implement a drug development program. Explore the unique considerations for drug product manufacturing.

Integrated biocatalysis and continuous processing are reshaping therapeutic manufacturing, enabling faster scale‑up, greater efficiency, and lower costs as peptides and oligonucleotides meet demands.

To ensure consistent drug supply, pharmaceutical companies must integrate operations and supply chain management for proactive planning and global risk mitigation.

View how to implement USP <665> extractables testing, align with global E&L standards, and apply risk-based strategies to ensure regulatory compliance and patient safety.

Early collaboration with an expert partner streamlines HME projects through optimized formulation, strong scale‑up, solid analytics, and adaptable technologies that boost performance.

A novel valve provides dual‑chamber functionality within standard syringes, keeping two liquid drugs separated until injection while reducing development risk through advanced modeling.

Selecting and engineering the right cell line is not simply a technical milestone; it is a strategic decision that shapes cost of goods, development timelines, and the overall probability of success.

Fill‑finish is evolving as biologics and advanced therapies shift capacity and sterility needs. Automation, emerging tech, and data‑driven methods are boosting efficiency in aseptic production.

Assimilate how the iCELLis500+ fixed-bed bioreactor supports the scalable manufacturing of both AAV and oncolytic virus therapies, detailing successful process development and scale-up strategies.

Explore the advancing mass spectrometry, biophysical characterization, automated sample preparation, and high throughput analytics required to deliver medicines in a safe, compliant, and efficient manner.

Embrace the future of drug development by leveraging AI and innovative protein synthesis technologies to accelerate the creation of effective therapies and transform patient outcomes.